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Abstract
Background: Molecular classification of breast cancer is an important prognostic factor. The distribution of
molecular subtypes of breast cancer and their prognostic value has not been well documented in Asians.
Methods: A total of 2,791 breast cancer patients recruited for a population-based cohort study were evaluated for
molecular subtypes of breast cancer by immunohistochemical assays. Data on clinicopathological characteristics
were confirmed by centralized pathology review. The average follow-up of the patients was 53.4 months. Overall
and disease-free survival by molecular subtypes of breast cancer were evaluated.
Results: The prevalence of the luminal A, luminal B, human epidermal growth factor receptor 2 (HER2), and triple-
negative subtypes were 48.6%, 16.7%, 13.7%, and 12.9%, respectively. The luminal A subtype was more likely to be
diagnosed in older women (P = 0.03) and had a stronger correlation with favorable clinicopathological factors
(smaller tumor size, lower histologic grade, and earlier TNM stage) than the triple-negative or HER2 subtypes.
Women with triple-negative breast cancer had a higher frequency of family history of breast cancer than women
with other subtypes (P = 0.048). The 5-year overall/disease-free survival percentages for the luminal A, luminal B,
HER2, and triple-negative subtypes were 92.9%/88.6%, 88.6%/85.1%, 83.2%/79.1%, and 80.7%/76.0%, respectively. A
similar pattern was observed in multivariate analyses. Immunotherapy was associated with improved overall and
disease-free survival for luminal A breast cancer, but reduced disease-free survival (HR = 2.21, 95% CI, 1.09-4.48) for
the HER2 subtype of breast cancer.
Conclusions: The triple-negative and HER2 subtypes were associated with poorer outcomes compared with the
luminal A subtype among these Chinese women. The HER2 subtype was more prevalent in this Chinese
population compared with Western populations, suggesting the importance of standardized HER2 detection and
anti-HER2 therapy to potentially benefit a high proportion of breast cancer patients in China.
Background
Breast cancer is highly heterogeneous with regard to
morphological spectrum, clinical presentation, and
response to cancer therapy [1]. Based on gene-expres-
sion profiling using cDNA microarray technology, a
molecular taxonomy has been proposed to classify
breast cancer into luminal A, luminal B, basal-like, and
HER2 subtypes, which have distinct differences in prog-
nosis and responses to cancer therapies [2,3]. Using
conventional immunohistochemistry (IHC) detection of
estrogen receptor-alpha (ERa), progesterone receptor
(PR), and human epidermal growth factor receptor 2
(HER2) status, molecular subtypes of breast cancer can
be classified as: luminal A (ERa+a n d / o rP R + ,H E R 2 - ) ,
luminal B (ERa+ and/or PR+, HER2+), triple-negative
(ERa-, PR- and HER2-), and HER2 (HER2+, ERa-, and
PR-) [4]. It has been suggested that the triple-negative
and HER2 subtypes defined by IHC have poorer survival
outcomes and respond differently to adjuvant che-
motherapy compared with the luminal A subtype [4,5].
Most previous studies were conducted in Western
populations, while few population-based studies have
been conducted in Asians.
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reported. For example, the triple-negative subtype
appears to be more common in African-American popu-
lations, especially among younger African-American
women, compared with European-ancestry populations
[4,6-8]. One study has suggested that the HER2 subtype
is more common in Asian populations and that the dis-
tribution of breast cancer subtypes among Asian women
may vary by ethnicity (i.e., Chinese, Japanese, etc.) [9]. A
few studies have evaluated the molecular subtypes of
breast cancer in Chinese women [10-14]. However,
most of those studies have had a relatively small sample
size and applied different criteria to define positivity.
For example, HER2 has been defined as positive with a
DAKO score of 3+ (>10% cells show strong complete
membrane staining) [10-12,14] or ≥2+ (>10% cells show
weak to moderate complete membrane staining) [13].
The widely used criteria for HER2 positivity modified by
the American Society of Clinical Oncology/College of
American Pathologists guidelines [15] were not used in
those publications. The prevalence and clinicopathologi-
cal significance of breast cancer subtypes in the Chinese
population merits verification. The present study used
data from a large-scale, population-based cohort study
of breast cancer patients in Shanghai, China [16]. The
distribution of molecular subtypes of breast cancer and
their correlation with breast cancer outcomes were
evaluated.
Methods
Participants
Study participants were women aged 20 to 75 years who
were diagnosed with a primary breast cancer and
enrolled in the Shanghai Breast Cancer Survival Study
(SBCSS), a longitudinal, population-based cohort study
in Shanghai, China [16]. Through the population-based
Shanghai Cancer Registry, 6,299 women were identified
approximately 6.5 months after a cancer diagnosis, and
5,042 were enrolled in the study (participation rate:
80.0%) between March 2002 and April 2006. The SBCSS
was approved by the institutional review boards of all
institutions involved in the study, and written informed
consent was obtained from all participants.
Data collection
Trained interviewers, all retired health professionals (e.
g., nurses and physicians), conducted in-person inter-
views using a standard baseline survey questionnaire to
collect information on demographic characteristics,
reproductive history, disease history, medication use,
selected lifestyle factors, diet, use of complementary and
alternative medicine, and quality of life. Clinical infor-
mation collected included cancer stage, tumor ERa and
PR status, and primary treatments. Inpatient medical
charts were reviewed to verify clinical information.
Anthropometric measurements, including height,
weight, and circumferences of the waist and hips, were
taken according to a standard protocol by trained inter-
viewers at the baseline interview. The cohort is being
followed up by in-person interviews that take place at
18 months, 36 months, and 60 months after cancer
diagnosis, supplemented by record linkage to the Shang-
hai Vital Statistics Registry.
Tissue slide preparation
Pathology slides for 2,791 cases were available for this
study. The slides were collected from the diagnosis hos-
pitals according a standard protocol. Briefly, the forma-
lin-fixed, paraffin-embedded blocks were cut in 5 μm
thick sections. The sectioned tissue slides were covered
with a thin layer of paraffin, and stored in vacuum
chambers (Terra Universal, Inc., Anaheim, CA) placed
in a 4°C cold room to properly preserve the antigenicity
of the sectioned tissues. This slide storage method has
been established and verified in our centralized labora-
tory [17]. The diagnoses and clinicopathologic data were
confirmed by a combination of medical chart review
and centralized review of pathology slides. The histolo-
gical types of breast cancer were confirmed according to
the criteria of the World Health Organization classifica-
tion [18] by the study pathologist (Su). The histologic
grade of all cancer slides was determined using the Not-
tingham histologic grading system [19].
Immunohistochemistry
HER2 staining was conducted for all 2,791 participants
included in this study in our centralized laboratory, with
rabbit polyclonal antibody recognizing the HER2 cyto-
plasmic domain (DAKO, Cat# A0485, 1:100), following
the protocol of the DAKO Envision™ kit (DAKO, Cat#
K4011). This staining protocol has been validated by
comparing it with the HercepTest™ kit (DAKO, Cat#
K5204) using commercial tissue microarray (TMA)
slides, which included tissue slides from 70 breast can-
cer cases (BR701, US Biomax Inc.). A 100% concordance
rate between the two methods was obtained. For
patients whose ERa (243 cases) and PR (222 cases) sta-
tus could not be obtained from medical charts, double
immunohistochemical staining for PR/HER2 and ERa/
estrogen receptor beta (ERb) was conducted. PR/HER2
double staining was performed using the EnVision™ G|
2 Doublestain System (Additional file 1). ERa/ERb dou-
ble immunofluorescent staining was performed using a
sequential double labeling protocol proposed by Vector
Laboratories (Additional file 2). The staining protocols
were carefully validated by comparison with standard
staining, using the above BR701 commercial TMA
breast cancer slides (Figures 1 and 2). We constructed a
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breast cancer tissue sample with positive expression of
ERa,E R b, and PR; one breast cancer tissue sample with
positive HER2 expression; and normal ovary, prostate,
and liver tissue samples (Figure 3). The control TMA
slides were stained in parallel with each batch of study
samples using an Autostainer Universal Staining System
(DAKO, Model LV-1).
Membrane staining intensity and the pattern of HER2
staining were evaluated using the 0 to 3+ scale [15].
Scores of 0 and 1+ (weak immunostaining in less than
30% of tumor cells) were defined as negative, 2+ (com-
plete membranous staining, in at least 10% but less than
30% of tumor cells) as equivocal, and 3+ (uniform
intense membranous staining in at least 30% of tumor
cells) as positive. For ERa staining, a clinically validated
threshold [20,21] for the prediction of response to hor-
monal therapy (>10% cutoff for whole slides) was used
in this study. PR expression was considered to be posi-
tive, if the nuclei of more than 1% of cells were stained
Figure 1 Double immunohistochemical staining for PR/HER2. To validate the lab staining method, commercial breast cancer tissue
microarray (TMA) slides BR701 (US Biomax Inc.) were used. D1, TMA core with HER2+ and PR- staining. D2, HER2- and PR+ staining. G1, HER2+
and PR+ staining. D9, PR+ and HER2 weak-positive (borderline) staining. PR/HER2 double stains were comparable to standard single stains for
HER2 and PR, although the PR signal in the double staining was somewhat weaker (original magnification: ×200).
Figure 2 Double immunofluorescence staining for ERa/ERb. The same commercial breast cancer TMA slides were used to validate ERa
staining. TMA cores C2 and C8, strong ERa nuclear staining. F10, weak ERa nuclear staining. F6, negative ERa staining. ERa fluorescent positive
signals were comparable to standard single staining for ERa (original magnification: ×100).
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ated independently by two investigators (Su and Li), and
all slides with inconsistent readings were re-evaluated by
the two investigators jointly and the final status
assigned.
Statistics
Differences in sociodemographic and clinicopathologic
characteristics across different breast cancer subtypes
were evaluated using the one-way analysis of variance
test for continuous variables (such as age), and the chi-
square test for categorical variables. Log-rank tests were
applied to evaluate differences in survival rates. Multi-
variate Cox proportional hazards models were employed
to evaluate associations of molecular subtypes with over-
all and disease-free survival rates. The following covari-
ates were adjusted in the multivariate models: age at
diagnosis, education, income, body mass index (BMI),
radiotherapy, chemotherapy, immunotherapy and
tamoxifen use, TNM stage, histologic grade, and tumor
size. All the tests were performed by using Statistical
Analysis Software (SAS, version 9.1; SAS Institute, Inc.,
Cary, North Carolina). The significance levels were set
at P < 0.05 for two-sided analyses.
Results
Distributions of baseline sociodemographic and clinico-
pathologic characteristics by 5-year survival rate for the
study population of 2,791 subjects are presented in
Table 1. The variables significantly related to 5-year sur-
vival were: age at diagnosis, education, income, TNM
stage, histologic grade and type, ERa, PR, HER2 status,
and use of adjuvant therapy (tamoxifen and radiother-
apy). The subpopulation of this study was similar to the
overall study population for the above characteristics
(data not shown).
Prevalences of the luminal A (ERa +a n d / o rP R + ,
HER2-), luminal B (ERa + and/or PR+, HER2+), HER2
(HER2+, ERa-, and PR-), and triple-negative (ERa-, PR-,
HER2-) subtypes were 48.6%, 16.7%, 13.7%, and 12.9%,
respectively. The 8.1% of cases that showed weak
positive staining of HER2 (scored as 2+) by IHC were
classified as the borderline or equivocal group in this
study. During an average of 53.4 months of follow-up
after cancer diagnosis, 290 total deaths and 341 recur-
rences/breast cancer-specific deaths were documented.
Differences among molecular subtypes with regard to
clinicopathologic characteristics were observed and are
presented in Table 2. Significant differences were
observed in age at cancer diagnosis (P = 0.03) with
luminal A breast cancer being more common among
older women (≥70) and triple-negative cancer more
common among younger women (<40). Women with
the luminal A subtype was more likely to have low
TNM stage (P < 0.01), smaller tumor size (P < 0.01),
and low histologic grade (P < 0.01) compared with
women with the HER2 and triple-negative subtypes.
Women with triple-negative breast cancer had a higher
frequency of family history of breast cancer than women
with other subtypes (P = 0.048).
We classified histological types of breast cancer into
four categories: non-invasive, invasive lobular, invasive
ductal, and invasive special types (data not shown in
tables). For non-invasive breast cancer (ductal carci-
noma in situ [DCIS] and lobular carcinoma in situ
[LCIS]), the most common molecular subtype was lumi-
nal A (42.7%), followed by luminal B (20.8%), and the
HER2 subtype (18.8%); the triple-negative subtype was
least common (10.4%). Among invasive cancers, luminal
A accounted for 66% of ILCs, luminal B for 10.7%, the
HER2 subtype for 3.7%, and triple-negative for 8.4%. For
IDCs, luminal A accounted for 43.3%, luminal B for
18.8%, the HER2 subtype for 16.3%, and triple-negative
for 13.1%. Luminal A was the most common molecular
subtype among the special histological types of breast
cancer (mucinous, 81.2%; papillary, 65.5%; mixed,
58.9%), except for medullary breast cancer where triple-
negative was most common (37.9%) (luminal A, 30%;
HER2 subtype, 19%).
Associations of molecular subtypes with 5-year overall
and disease-free survival rates are presented in Table 3.
Women with the luminal A, luminal B, HER2, and
Figure 3 Double immunofluorescence staining for ERa/ERb using lab-constructed TMA control slides. For immunostaining quality
control, lab-constructed slides were stained with each batch. One TMA core of breast tissue exhibited strong ERa and ERb nuclear staining in
tumor cells (T), other than normal epithelium (N). Most tumor cells exhibited co-expression of ERa and ERb, as revealed in the overlapping
image (original magnification: ×200).
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survival rates of 92.9/88.6, 88.6/85.1, 83.2/79.1, and
80.7/76.0, respectively. Multivariate Cox regression ana-
lyses showed that the HER2 and triple-negative subtypes
were associated with an increased risk of overall mortal-
ity (hazard ratio (HR) = 1.47, 95% CI, 1.03 to 2.10;
HR = 1.87, 95% CI, 1.31 to 2.66, respectively) and breast
cancer recurrence/disease-related mortality (HR = 1.32,
95% CI, 0.95 to 1.83; HR = 1.52, 95% CI, 1.09 to 2.11,
respectively) after adjustment for age, education,
income, BMI, radiotherapy, chemotherapy, immunother-
apy, tamoxifen use, TNM stage, histologic grade, and
tumor size. A total of 477 cases in our study received
some forms of immunotherapy, including IL-2, lympho-
kine-activated killer cell, and interferon. Immunotherapy
was associated with improved overall survival (HR =
0.27, 95% CI, 0.10 to 0.69) and disease-free survival (HR
= 0.41, 95% CI, 0.20-0.82) for luminal A breast cancer,
but reduced disease-free survival (HR = 2.21, 95% CI,
1.09-4.48) for the HER2 subtype of breast cancer. Use of
immunotherapy was not significantly associated with
Table 1 Selected demographic and clinical characteristics
of breast cancer patients included in the Shanghai Breast
Cancer Survival Study.
Variables Levels Number
of cases
% 5-year
survival
rate
P
Age at
diagnosis
<40 126 4.51 0.9029 <0.01
40-49 1128 40.42 0.9166
50-59 794 28.45 0.8827
60-69 469 16.8 0.8586
≥70 274 9.82 0.8356
Education <Middle
School
361 12.93 0.7941 <0.01
Middle
School
988 35.40 0.8948
> Middle
School
1442 51.67 0.9096
Income <1,000 1723 61.73 0.8696 <0.01
(CNY¥/person/
month)
1,000 - 1,999 777 27.84 0.9141
≥2,000 291 10.43 0.9415
TNM stage 0 63 2.26 1.0000 <0.01
I 871 31.21 0.9545
IIa 945 33.86 0.9221
IIb 549 19.67 0.8174
III-IV 272 9.75 0.6724
Histologic
grade
I 438 15.69 0.9611 <0.01
II 1312 47.01 0.9002
III 803 28.77 0.8274
Unknown 238 8.53 0.9231
Histologic type* Noninvasive
(DCIS, LCIS)
96 3.44 1.0000 <0.01
ILC NOS 215 7.70 0.8797
IDC NOS 1924 68.94 0.8745
Special types 527 18.88 0.9264
Unknown 29 1.04 0.8966
ERa Positive
(> = 10%)
1740 62.34 0.9206 <0.01
Negative 1051 37.66 0.8354
PR Positive
(> = 1%)
1632 58.47 0.9183 <0.01
Negative 1159 41.53 0.8465
HER2 Positive (3+) 849 30.42 0.8621 0.02
Borderline
(2+)
227 8.13 0.8768
Negative
(0-1+)
1715 61.45 0.9032
Table 1 Selected demographic and clinical characteristics
of breast cancer patients included in the Shanghai Breast
Cancer Survival Study. (Continued)
Molecular
subtype**
Luminal A 1355 48.55 0.9286 <0.01
Luminal B 467 16.73 0.8862
HER2 382 13.69 0.8322
Triple
negative
360 12.90 0.8069
HER2
borderline
227 8.13 0.8768
Radiotherapy Yes 874 31.31 0.8409 <0.01
No 1917 68.69 0.9098
Chemotherapy Yes 2558 91.65 0.8890 0.99
No 233 8.35 0.8818
Immunotherapy Yes 477 17.09 0.9118 0.18
No 2310 82.77 0.8844
Unknown 4 0.14 0.7500
Tamoxifen *** Yes 1484 53.17 0.9123 <0.01
No 1306 46.79 0.8612
*DCIS: ductal carcinoma in situ; LCIS: lobular carcinoma in situ; IDC NOS:
invasive ductal carcinoma not otherwise specified; ILC NOS: invasive lobular
carcinoma not otherwise specified; Special types: including mucinous,
papillary, medullary, tubular, cribriform, metaplastic, mixed, and other rare
invasive cancers.
** Luminal A: ERa+ and/or PR+, HER2-; luminal B: ERa+ and/or PR+, HER2+;
HER2: HER2+, ERa-, and PR-; triple negative: ERa-, PR-, HER2-: HER2 borderline:
weak staining of HER2 (2+).
***One case with unknown tamoxifen use was excluded.
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breast cancers.
Discussion
Distribution of molecular subtypes of breast cancer in
Chinese women
Our study showed that the prevalence of the triple-
negative subtype of breast cancer among Chinese
women (12.9%) is similar to that in European popula-
tions (10-16%), but lower than in African-American
population (20-21%). The HER2 subtype accounted for
13.7% of Chinese breast cancer cases, which is higher
than the reported positivity (4-8%) in either European
or African-American populations [4,6-8,22,23]. In our
study, approximately 8% of breast cancer patients had
weak positive or borderline staining (2+) for HER2,
Table 2 Comparisons of clinical and tumor characteristics by molecular subtypes of breast cancer, the Shanghai Breast
Cancer Survival Study.
Covariables Levels Luminal A Luminal B HER2 Triple-negative HER2 borderline P value
N = 1355 N = 467 N = 382 N = 360 N = 227
No. (%) No. (%) No. (%) No. (%) No. (%)
Mean age at diagnosis* 54.1(10.2) 52.3 (9.3) 53.4 (9.7) 53.5 (10.7) 53.1 (9.9) 0.03
Age at diagnosis 0.02
<30 3 (0.22) 2 (0.43) 1 (0.26) 4 (1.11) 1 (0.44)
30-39 47 (3.47) 21 (4.50) 16 (4.19) 22 (6.11) 9 (3.96)
40-49 556 (41.03) 201 (43.04) 138 (36.13) 134 (37.22) 99 (43.61)
50-59 364 (26.86) 148 (31.69) 125 (32.72) 97 (26.94) 60 (26.43)
60-69 230 (16.97) 63 (13.49) 70 (18.32) 67 (18.61) 39 (17.18)
≥70 155 (11.44) 32 (6.85) 32 (8.38) 36 (10.00) 19 (8.37)
Pre-menopausal 661 (48.78) 239 (51.18) 167 (43.72) 174 (48.33) 114 (50.22) 0.27
Family history of breast cancer 61 (4.50) 21 (4.50) 17 (4.45) 28 (7.78) 17 (7.49) 0.048
TNM stage 0 32 (2.36) 11 (2.36) 8 (2.09) 7 (1.94) 5 (2.20) <0.01
I 473 (34.91) 124 (26.55) 91 (23.82) 98 (27.22) 85 (37.44)
IIa 452 (33.36) 165 (35.33) 135 (35.34) 122 (33.89) 71 (31.28)
IIb 240 (17.71) 98 (20.99) 88 (23.04) 76 (21.11) 47 (20.70)
III-IV 109 (8.04) 55 (11.78) 51 (13.35) 42 (11.67) 15 (6.61)
Tumor size, cm * 2.80 (1.91) 3.31 (3.03) 3.34 (2.26) 3.14 (1.57) 2.82 (1.73) <0.01
Histologic grade I 306 (22.58) 31 (6.64) 17 (4.45) 48 (13.33) 36 (15.86) <0.01
II 736 (54.32) 217 (46.47) 140 (36.65) 106 (29.44) 113 (49.78)
III 219 (16.16) 159 (34.05) 190 (49.74) 175 (48.61) 60 (26.43)
Histologic type Noninvasive** 41 (3.03) 20 (4.28) 18 (4.71) 10 (2.78) 7 (3.08) <0.01
ILC NOS 142 (10.48) 23 (4.93) 8 (2.09) 18 (5.00) 24 (10.57)
IDC NOS 834 (61.55) 361 (77.30) 314 (82.20) 253 (70.28) 162 (71.37)
Special types 318 (23.47) 60 (12.85) 39 (10.21) 76 (21.11) 34 (14.98)
* Number presented as mean (standard deviation)
**Including DCIS and LCIS.
Table 3 Molecular subtypes in association with breast cancer survival, the Shanghai Breast Cancer Survival Study.
Overall survival Disease-free survival
Cases Events 5-yr survival
rate
HR1* (95% CI) HR2** (95% CI) Cases Events 5-yr survival
rate
HR1* (95% CI) HR2** (95% CI)
Luminal A 1258 97 0.9286 1.00 1.00 1234 121 0.8863 1.00 1.00
Luminal B 419 48 0.8862 1.57 (1.10 - 2.22) 1.17 (0.82 - 1.68) 410 57 0.8506 1.42 (1.03 - 1.95) 1.04 (0.75 - 1.43)
HER2 322 60 0.8322 2.12 (1.50 - 3.00) 1.47 (1.03 - 2.10) 312 70 0.7907 1.94 (1.41 - 2.67) 1.32 (0.95 - 1.83)
Triple-
negative
298 62 0.8069 2.50 (1.78 - 3.51) 1.87 (1.31 - 2.66) 292 68 0.7600 2.12 (1.55 - 2.91) 1.52 (1.09 - 2.11)
HER2
borderline
204 23 0.8768 1.46 (0.93 - 2.32) 1.42 (0.90 - 2.26) 202 25 0.8788 1.19 (0.77 - 1.84) 1.15 (0.75 - 1.79)
*HR1: Adjusted for age, education, income, BMI, radiotherapy, chemotherapy, immunotherapy, and tamoxifen use.
**HR2: Further adjusted for TNM, histologic grade, and tumor size
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would be recommended for verification with fluorescent
in situ hybridization (FISH) for therapeutic indication of
trastuzumab (Herceptin) treatment [15]. The FISH-
derived amplification rate for the HER2 equivocal group
(i.e., IHC 2+) has been observed to be approximately
25% in Western women [24,25]. If a similar rate is true
for Chinese women, most HER2 equivocal cases would
fall into either luminal A or triple-negative subtypes.
Therefore, the frequencies of luminal A (48.6%) and tri-
ple-negative subtypes in our study could be underesti-
mated. We compared ER and PR status for the HER2
borderline group with the HER2+ and HER2- groups,
and found that ER+ and PR+ rates (67.4% and 57.7%,
respectively) for the HER2 borderline group were more
similar to that of the HER2- group (69.7% and 67.1%,
respectively) than to the HER+ group (46.1% and 41.3,
respectively), suggesting that the vast majority of cases
in our HER2 borderline group should likely be classified
in the HER2- group. Regardless of the true HER2+ rate
for the borderline group, the prevalence of the HER2
subtype in this Chinese population is higher than in
Western populations.
The prevalence of breast cancer subtypes appears to
differ among different races or ethnicities. It has been
well documented that the triple-negative subtype is
most common among young African-American patients,
while luminal A is most common among postmenopau-
sal white women [4,6-9,22,23]. The increased risk for
the triple-negative subtype in African-American women
may due to parity and younger age at first full-term
pregnancy, multiple live births without breastfeeding,
use of medications to suppress lactation [7], and intrin-
sic genetic variables, such as higher p53 expression [6]
and particularly high prevalence of founder mutations in
BRCA1 or BRCA2 gene in young( < 3 5y e a r s )A f r i c a n -
American women [26]. In our study population, women
with triple-negative breast cancer more frequently
reported a family history of breast cancer than did
women with other subtypes. This suggests that genetic
factors may play a more important role in this molecu-
lar subtype of breast cancer. Since BRCA mutations in
Chinese women are uncommon (1.1% each for BRCA1
and BRCA2) [27]; other genetic contributors to the tri-
ple-negative subtype inC h i n e s ew o m e nn e e dt ob e
investigated.
We found that HER2+ breast cancers account for 30%
of all breast cancer cases in our study population, simi-
lar to a previous report from Shanghai (31%) and higher
than the reports from Tianjin (26%) [13,14], Taiwan
(21%) [28], and the US (26%) [9]. Consistent with our
findings, one large, registry-based population study [8]
showed that HER2+ tumors are more common among
Asian/Pacific Islanders (28%) than among non-Hispanic
Whites (21%) or non-Hispanic Blacks (24%), but similar
to Hispanics (26%) (Table 4). Another large population
study further revealed that among Asian-Americans,
Korean and Philipino women had the highest prevalence
of HER2+ tumors (36% and 31%, respectively), followed
by Vietnamese (29%) and Chinese (26%) women, while
Japanese and South Asian women showed a prevalence
of HER2+ tumors similar to non-Hispanic Whites and
non-Hispanic Blacks (19-23%) [9]. It was not clear why
t h ep r e v a l e n c eo ft h eH E R 2s u b t y p eo ro fH E R 2 +
tumors is higher among Chinese or Asian women com-
pared with women of European ancestry or African-
American women. Although it has been suggested that
environmental factors might play an important role in
the etiology of HER2+ breast cancers, variations in cri-
teria used to determine HER2 status may also contribute
the differences.
Prognostic significance of breast cancer subtypes among
Chinese women
C h i n e s ew o m e nw i t ht h et r i p l e - n e g a t i v es u b t y p ew e r e
younger in age at diagnosis compared with women who
had other subtypes of breast cancer, which is similar to
findings reported in Western populations [7,29]. The tri-
ple-negative subtype was associated with larger tumor
size, higher histologic grade, later TNM stage, and higher
prevalence in IDC than in ILC. These clinicopathologic
characteristics have been consistently observed in both
Western [4,8] and Chinese populations [10-13], suggest-
ing that the triple-negative subtype is an aggressive sub-
type of breast cancer across all ethnicities. Multivariate
analysis confirmed that the triple-negative subtype is an
independent prognostic factor for the progression and
survival of breast cancer. Most triple-negative cancers
defined by IHC present a basal-like subtype profile
defined by cDNA microarray, but they do not completely
correlate in about 25% of cases [30]. Other molecular
subsets may be included in triple-negative cancers.
Further epidemiological and biomarker studies for this
important subtype in Chinese women is necessary.
The HER2 subtype was closely correlated with larger
tumor size and higher histologic grade, consistent with
previous reports in other Chinese studies [10-13]. We
found that the HER2 subtype was associated with earlier
age at diagnosis, more advanced TNM stage, and
reduced 5-year overall and disease-free survival rates.
Anti-HER2 therapy is currently available. Our study sug-
gests that about 30% of Chinese women with the HER2
subtype (14%) or with the luminal B subtype (17%) may
benefit from trastuzumab (Herceptin) and other targeted
therapies, if HER2 status were evaluated following
the standardized HER2 evaluation guidelines [15] and
this information were incorporated into therapeutic
decisions.
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Page 7 of 11The luminal B subtype in our study was correlated
with younger age at diagnosis, more advanced TNM
stage, larger tumor size, higher histologic grade, and was
less common in the ILC and special histologic types
compared with the luminal A subtype. However, after
adjusting for TNM stage, histologic grade, and tumor
size, we observed no statistically significant differences
for overall or disease-free survival between the two
luminal subtypes. Currently, the definition of the lumi-
nal B subtype remains debatable. The luminal B subtype
originally classified using cDNA microarray gene profil-
ing was unstable and sometimes clustered with the ER-
classes (HER2 and basal subtypes) [31,32]. Approxi-
mately 30-50% of luminal B class samples defined by
gene profiling were HER2+. Therefore, the IHC defini-
tion of luminal B (ERa+a n d / o rP R + ,H E R 2 + )i sn o t
equivalent to the luminal B tumors classified with
m i c r o a r r a yg e n ep r o f i l i n g[ 4 ] .S i n c et h eg e n ep r o f i l e -
classified luminal B subtype is defined as tumors with
lower expression levels of ERa/PR and related genes,
higher proliferative rates, and higher histologic grade
[32], some authors have suggested that ERa expression
in tumor cells should be semi-quantified using the
Allred, Q-score, or H-score to distinguish luminal B
from luminal A [33]. More recently, a study [34] sug-
gested that the Ki67 index for cellular proliferation
should be combined with ERa, PR, and HER2 to classify
luminal tumors into three subtypes: luminal A (ERa+
and/or PR+, HER2-, Ki67 low), luminal B (ERa+a n d / o r
PR+, HER2-, Ki67 high), and luminal-HER2 (ERa+a n d /
or PR+, HER2+). In that study, the luminal B and lumi-
nal-HER2 subtypes had a statistically significant associa-
tion with poor breast cancer recurrence-free and
disease-specific survival in all adjuvant systemic
Table 4 Distribution of breast cancer subtypes in different ethnicities and in different geographical areas of China, %
References Ethnicity Luminal A Luminal B HER2 All HER2+* Triple-negative Unclassified Total No.
Carey, et al [4] AA 47.4 12.8 8.2 20.9 26.5 5.1 196
Caucasian 54.0 17.3 5.7 23.0 16.0 7.0 300
Yang, et al [23] Polish 68.0 14.0 5.0 19.0 13.0 1985
Varcone, et al [22] Italy 68.7 6.0 7.6 13.6 11.8 6.0 804
Parise, et al [8] Non-Hispanic White 67.1 15.1 6.2 21.3 11.6 39051
Non-Hispanic Black 48.9 14.2 9.8 24.0 27.0 2936
Hispanic 56.2 16.5 9.7 26.2 17.6 7673
Asian/Pacific Islander 59.3 18.5 9.9 28.4 12.3 5215
Other 65.1 14.3 5.4 19.7 15.2 315
Telli, et al [9] Non-Hispanic White 69.6 18.7 11.7 60498
Non-Hispanic Black 51.1 22.7 26.2 5292
Hispanic 58.1 24.9 17.0 14106
Japanese 69.9 19.5 10.7 1136
Chinese 63.5 25.6 10.8 2305
Filipino 59.2 30.7 10.1 2802
Korean 49.4 36.0 14.6 628
Vietnamese 56.6 29.3 14.1 663
South Asian 59.2 23.1 17.7 606
Other Asian** 58.2 28.9 12.9 973
Yin, Liu, Lin, et al [10-12] Chinese (Shanghai) 50.4 31.1 18.5 4787
Xing, Zhao, et al [13,14] Chinese (Tianjin) 53.7 14.0 11.8 25.8 20.5 3237
Lin, et al [28] Chinese (Taiwan) 61.8 8.8 11.8 20.5 12.8 4.9 1028
Su, et al (this study) Chinese (Shanghai) 48.6 16.7 13.7 30.4 12.9 8.1 2791
*All HER2+ tumors include luminal B and HER2 subtypes
**Includes women of Asian Indian, Pakistani, Sri Lankan, and Bangladeshi ethnicity
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Page 8 of 11treatment categories. Additional research is warranted to
determine the clinical utility of new methods to distin-
guish luminal breast cancers.
The immune system is thought to play an important
role in the metastatic cascade among cancer patients.
Thus, various immune strategies have been tested as
therapy for breast cancer, including vaccine therapy,
administration of exogenous cytokines, monoclonal anti-
bodies, and gene therapy [35]. In our study, we collected
general information on immunotherapy by asking parti-
cipants whether they had received immunotherapies
such as IL-2, lymphokine-activated killer (LAK) cell, and
interferons. We found that use of immunotherapy was
associated with improved overall and disease-free survi-
val among women with the luminal A subtype but with
reduced disease-free survival among women with the
HER2 subtype, suggesting that choosing the proper
immunotherapeutic method should be based on the
molecular characteristics of the tumor. This also indi-
cates that analysis of molecular subtypes of breast can-
cer has significance for personalized immunotherapy to
improve the survival of breast cancer patients.
In our study, we found that the molecular subtype of
breast cancer is not always consistent with histological
type in terms of predicting breast cancer outcomes. For
example, in our study, medullary breast cancers
accounted for about 19% of the HER2 subtype and 38%
of triple-negative cases. Medullary breast cancer is gen-
erally considered to be a favorable histological type of
breast cancer with a good prognosis. The unfavorable
molecular subtypes among medullary breast cancer
might not mean an unfavorable outcome. These results
suggest that breast cancer is more heterogonous than
the four molecular subtypes as defined by ER, PR, and
HER2 status. Further investigation into molecular het-
erogeneity is warranted.
This study is the largest population-based study on
molecular subtypes of breast cancer and survival among
Chinese women. This study has several notable
strengths. The population-based study design and high
overall response rate (80%) minimized potential selec-
tion bias. Standardized staining and scoring of HER2
status, and centralized pathological confirmation of
diagnosis minimized misclassification. There are also
some limitations to this study. For example, ERa and
PR status for the majority of participants (91% and
92%) was obtained from medical charts. Approximately
8% of cases with borderline positivity for HER2 as
determined by IHC were not evaluated with FISH. For
cases with missing ERa (234 cases) or PR status (222
cases), ER/PR status was measured at the Vanderbilt
centralized laboratory using a cut-off for ER positivity
of >10%, which is the cut-off used by the large hospitals
in Shanghai [10] and had been validated for the
prediction of response to hormonal therapy [20,21].
Due to a slightly decreased PR sensitivity of HER2/PR
double staining, a lower cut-off positivity value (>1%)
was used for PR positivity. To evaluate the potential
influence of the variation in the criteria used to define
ER and PR status, we performed additional analysis by
excluding cases whose ER and PR status were measured
at the centralized laboratory. We did not observe appre-
ciable changes in the study results. In 2010, the Ameri-
can Society of Clinical Oncology/College of American
Pathologists recommended that ERa and PR should be
considered positive, if there are at least 1% positive
tumor nuclei in the tissue samples with proper controls
[36]. If the recommended 1% cut-off value for ERa and
PR positivity were used in this study, the number of
HER2 and triple-negative subtypes would decrease and
the number of luminal subtypes would increase. How-
ever, the overall prevalence of HER2+ tumors, which
includes the luminal B and HER2 subtypes, would not
be affected. Future studies on breast cancer subtypes
using recommended guidelines [15,36] for hormone
receptors and HER2 status are warranted. In addition,
the follow-up period of this cohort is relatively short.
Our ongoing follow-up with the cohort would overcome
this limitation and allow an examination of the long-
term effects of different molecular subtypes on the sur-
vival of breast cancer patients.
Conclusions
This large population-based study of Chinese breast
cancer survivors confirmed that the triple-negative and
HER2+ subtypes were associated with poorer outcomes
compared with the luminal A subtype among Chinese
women. The HER2+ subtype was more prevalent in this
Chinese population compared with Western popula-
tions, suggesting the importance of standardized HER2
detection and anti-HER2 therapy to potentially benefit a
high proportion of breast cancer patients in China.
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